Dravet Syndrome clinical trials at UCSF
5 in progress, 1 open to eligible people
ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
open to eligible people ages 6 months to 17 years
ENDEAVOR is a Phase 1/2, 2-part, multicenter study to evaluate the safety and efficacy of ETX101 in participants with SCN1A-positive Dravet syndrome aged ≥6 to <36 months (Part 1A), aged ≥48 months to <18 years (Part 1B), and aged ≥6 to <48 months (Part 2). Part 1A follows an open-label, dose-escalation design, Part 1B follows an open-label design, and Part 2 is a randomized, double-blind, sham delayed-treatment control study.
San Francisco, California and other locations
Intermediate-Size Expanded Access Protocol (EAP) for LP352
Sorry, not accepting new patients
This is an intermediate-size expanded access program (EAP) study. The purpose of this EAP is to provide continued access to LP352, an investigational drug product being investigated in participants with DEEs. The EAP study will allow continued treatment with LP352 for eligible participants diagnosed with treatment resistant DEEs who successfully completed an LP352 Clinical Trial (Enrollment by Invitation) or an immediate family member who has the exact same gene mutation resulting in the same DEE epilepsy syndrome phenotype or a patient who previously participated in the lorcaserin EAP.
San Francisco, California and other locations
LP352 in Children and Adults With Dravet Syndrome (DS)
Sorry, in progress, not accepting new patients
This (DEEp SEA Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DS. The study consists of 3 main phases: Screening, Titration period, and Maintenance period, followed by a Taper period and Follow-Up. Participants will be randomized to LP352 or placebo. The total duration of the study will be approximately 24 months.
San Francisco, California and other locations
STK-001 for Patients With Dravet Syndrome
Sorry, in progress, not accepting new patients
Stoke Therapeutics is evaluating the long-term safety & tolerability of repeated doses of zorevunersen (STK-001) in patients with Dravet syndrome who previously participated in studies of zorevunersen. Change in seizure frequency and overall clinical status, and quality of life will be measured as secondary endpoints in this open-label study.
San Francisco, California and other locations
Zorevunersen in Patients With Dravet Syndrome
Sorry, in progress, not accepting new patients
The purpose of the study is to evaluate the efficacy, safety, and tolerability of zorevunersen in Patients with Dravet syndrome.
San Francisco, California and other locations
Our lead scientists for Dravet Syndrome research studies include Adam Numis Nilika Singhal.
Last updated: